Oral Intake of L-Ornithine-L-Aspartate Is Associated with Distinct Microbiome and Metabolome Changes in Cirrhosis

Oral Intake of L-Ornithine-L-Aspartate Is Associated with Distinct Microbiome and Metabolome Changes in Cirrhosis

L-ornithine L-aspartate (LOLA) is administered as a therapeutic and/or preventive strategy against hepatic encephalopathy either intravenously or orally in patients with liver cirrhosis. Here, we analyzed how LOLA influences the microbiome and metabolome of patients with liver cirrhosis. We retrospe...

Full description

Bibliographic Details
Main Authors: Angela Horvath, Julia Traub, Benard Aliwa, Benjamin Bourgeois, Tobias Madl, Vanessa Stadlbauer
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Nutrients
Subjects:
microbiome
metabolome
L-ornithine-L-aspartate
cirrhosis
hepatic encephalopathy
Online Access:https://www.mdpi.com/2072-6643/14/4/748

Internet

https://www.mdpi.com/2072-6643/14/4/748

Similar Items